BTIG Reiterates Buy on Humacyte, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman has reiterated a Buy rating on Humacyte (NASDAQ:HUMA) and maintained a $10 price target.
October 18, 2024 | 2:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Ryan Zimmerman has reiterated a Buy rating on Humacyte and maintained a $10 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $10 price target by a reputable analyst suggests a positive outlook for Humacyte. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100